Saturday 17 October 2026 Export IMMP’s income statement to Excel — free account

Prima BioMed Ltd

Prima BioMed Ltd’s revenue for fiscal 2026 (year ended June 2026) was $16.4 million, up 145.2% from fiscal 2025. Revenue growth for three consecutive years.

3.20 0.01 −0.31%

Follow IMMP

Alert me

Market cap: $23.7M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: 3/9
Altman Z: −10.45
Beneish M: −3.49
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 23.66

Revenue —

Net Income 0.00

Free Cash Flow (42.34)

Net Debt (64.76)

Current Ratio 2.97

Debt/Equity 0.01

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.05

Past 5Y EPS Growth —

This Y EPS Growth 81.03%

Next Y EPS Growth 25.46%

Next Y revenue growth —

Next 5Y EPS Growth 48.66%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 50.29%

10-year low 10-year high

EV/FCF against its own 10 years 46.92%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	83	119	84	47
Receivables	5	5	6	6
Inventory	—	—	—	—
Other	2	1	6	2
	91	125	97	55

	2023	2024	2025	2026
Payables	6	6	7	9
ST’ Debt	—	—	1	—
Other	—	—	—	—
	7	7	8	10

Compound Annual Growth %

	10y	5y	3y
Sales	27.21%	40.79%	67.34%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	4.96%	(5.27%)	(23.11%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	—	16
’25	—	—	—	—	7
’24	—	—	—	—	5
’23	—	—	—	—	4
’22	—	—	—	—	5
’21	—	—	—	—	3

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	(19)	(38)
’25	—	—	—	(19)	(40)
’24	—	—	—	—	(23)
’23	—	—	—	—	(24)
’22	—	—	—	—	(22)
’21	—	—	—	—	(13)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	(19)	(38)
’25	—	—	—	(19)	(40)
’24	—	—	—	0	(23)
’23	—	—	—	0	(24)
’22	—	—	—	0	(22)
’21	—	—	—	0	(13)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	—	(7.32)
’25	—	—	—	—	(5.47)
’24	—	—	—	—	(4.66)
’23	—	—	—	—	(6.02)
’22	—	—	—	—	(5.51)
’21	—	—	—	—	(7.51)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	1.25	1.60	1.27	0.53	2.20	1.47	1.50	1.66	1.32	0.26	Analyst estimates 2027–2029 Powerpack
	High	3.24	4.21	3.23	7.95	5.44	3.64	3.90	3.34	3.53	5.36
People
People	Employees	17	19	24	26	28	35	35	44	51	—
	Revenue/emp, $m	0.19	0.30	0.22	0.43	0.11	0.14	0.10	0.12	0.13	0.00
Income, $m
Income, $m	Revenue	3	6	5	11	3	5	4	5	7	16
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(8)	(10)	(13)	(9)	(22)	(23)	(27)	(28)	(40)	(54)
	EBT margin, %	(239.36)	(173.32)	(244.93)	(81.63)	(753.56)	(476.62)	(767.22)	(544.95)	(594.64)	(328.13)
	Net income	(7)	(10)	(13)	(9)	0	(23)	(27)	(28)	(40)	(54)
	Depreciation	1	1	1	1	—	1	1	1	2	2
Per share, $
Per share, $	Revenue	3.07	4.37	3.32	5.53	1.00	1.16	0.78	0.86	0.92	2.23
	Earnings	(6.82)	(7.58)	(8.13)	(4.51)	(7.51)	(5.51)	(6.02)	(4.66)	(5.47)	(7.32)
	Cash flow	(6.19)	(4.62)	(6.78)	(3.63)	(4.43)	(5.17)	(5.33)	(3.80)	(5.52)	(5.12)
	Capex	0.00	(0.01)	(0.02)	(0.01)	0.00	0.00	(0.01)	(0.10)	(0.02)	(0.01)
	Free cash flow	(6.19)	(4.63)	(6.80)	(3.64)	(4.44)	(5.17)	(5.35)	(3.90)	(5.54)	(5.12)
	Book value	19.30	19.93	10.81	11.15	18.41	16.08	20.59	20.70	12.78	5.68
	Shares, m	1	1	2	2	3	4	4	6	7	7
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	P/S	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/B	0.10	0.12	0.08	0.06	0.09	0.03	0.04	0.03	0.02	0.01
	EV/Sales	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	EV/FCF	0.15	0.14	0.18	0.45	2.04	3.17	1.40	1.71	3.06	1.42
Cash, $m
Cash, $m	Operating cash flow	(6)	(6)	(11)	(7)	(13)	(22)	(24)	(23)	(40)	(38)
	Capex	0	0	0	0	0	0	0	(1)	0	0
	Free cash flow	(6)	(6)	(11)	(7)	(13)	(22)	(24)	(23)	(40)	(38)
Balance, $m
Balance, $m	Working capital	10	19	13	19	47	61	84	119	88	45
	Total debt	4	5	5	6	2	1	1	1	1	—
	Net debt	(5)	(13)	(6)	(12)	(43)	(57)	(83)	(119)	(83)	(47)
	Shareholders’ equity	20	26	17	22	55	68	92	124	93	42
Returns, %
Returns, %	ROA	(24.62)	(31.47)	(40.10)	(30.00)	(48.27)	(34.51)	(30.98)	(24.21)	(34.02)	(68.06)
	ROIC	(29.12)	(43.76)	(70.12)	(48.85)	(80.32)	(128.28)	(178.93)	(309.31)	(248.37)	0.00
	ROE	(30.88)	(42.97)	(60.41)	(45.44)	(57.95)	(38.00)	(33.55)	(25.92)	(36.62)	(79.87)

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Mar 2017 · fundamentals updated 2 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MCRB Seres Therapeutics, Inc.	$25.2M	— (loss-making)	— (loss-making)	+96.79% (above 0%: growing)	n/m	−66.15% (below 0%: shrinking)	100.00%	(2,890.35%)	Compare
ABVC ABVC BioPharma, Inc.	$24.9M	— (loss-making)	— (loss-making)	+66,233.33% (above 0%: growing)	n/m	+72.66% (above 0%: growing)	100.00%	0.00%	Compare
BYSI BeyondSpring Inc.	$23.9M	— (loss-making)	— (loss-making)	+87.78% (above 0%: growing)	n/m	+35.78% (above 0%: growing)	100.00%	0.00%	Compare
CYAD Celyad SA	$23.8M	— (loss-making)	— (loss-making)	—	n/m	+78.72% (above 0%: growing)	0.00%	0.00%	Compare
PLRZ Polyrizon Ltd.	$23.7M	—	—	—	—	−744.51% (below 0%: shrinking)	—	—	Compare
IMMP Prima BioMed Ltd	$23.7M	— (loss-making)	—	—	n/m	−589,653.13% (below 0%: shrinking)	100.00%	(101.89%)
EVAX Evaxion A/S - Sponsored ADR	$23.4M	— (loss-making)	— (loss-making)	+14,590.20% (above 0%: growing)	n/m	−56.70% (below 0%: shrinking)	100.00%	0.00%	Compare
ESLA Estrella Immunopharma, Inc.	$23.3M	— (loss-making)	—	—	n/m	−329.19% (below 0%: shrinking)	—	0.00%	Compare
CNTX Context Therapeutics Inc.	$22.1M	— (loss-making)	—	—	n/m	−20.61% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$23.8M	—	—	+7,343.49%	—	−38.65%	100.00%	0.00%

All 614 Biotechnology stocks →

Prima BioMed Ltd (IMMP) key facts

Strength: Prima BioMed Ltd’s revenue for fiscal 2026 (year ended June 2026) was $16.4 million, up 145.2% from fiscal 2025.
Prima BioMed Ltd (IMMP) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, IMMP traded at $3.20, a market capitalization of $23.7 million.
Return on equity was −79.9% and debt-to-equity 0.01.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −10.45 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 2, 2026.